GLAND vs GRANULES: Stock Comparison

Gland Pharma Limited vs Granules India Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Gland Pharma Limited is the larger company by market capitalisation. Gland Pharma Limited shows a higher dividend yield, lower leverage and a higher net margin, while Granules India Limited shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Gland Pharma Limited and Granules India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, GLAND is more favourable on 8 of 13 scored metrics and GRANULES on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GLAND is the larger company
₹40,034 Cr vs ₹20,831 Cr
P/E Ratio
GRANULES has a lower P/E
31.63x vs 39.05x
P/B Ratio
GLAND has a lower P/B
3.87x vs 4.16x
EPS
GLAND has higher earnings per share
₹62.35 vs ₹26.92
Dividend Yield
GLAND has a higher dividend yield
0.84% vs 0.21%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 22.3%
EPS Growth (TTM YoY)
GLAND has faster EPS growth
96.4% vs 31.3%
Qtr Sales Growth
GRANULES has stronger quarterly sales growth
22.8% vs 22.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGLANDGRANULES
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGLANDGRANULES
Live Price₹2,428.3₹845.4
Day Change0.05%0.31%
Volume1.43 L7.05 L
52-Week High₹2,573.5₹910
52-Week Low₹1,573.6₹432.6
Distance from 52W High-5.64%-7.1%

Valuation

MetricGLANDGRANULES
Market Cap₹40,034 Cr₹20,831 Cr
P/E Ratio39.05x31.63x
P/B Ratio3.87x4.16x
EPS₹62.35₹26.92
Book Value₹628.81₹205.21
Dividend Yield0.84%0.21%

Growth

MetricGLANDGRANULES
Revenue Growth (TTM YoY)22.3%22.8%
EPS Growth (TTM YoY)96.4%31.3%
Qtr Sales Growth22.3%22.8%
Qtr Profit Growth96.6%44.6%

Profitability & Leverage

MetricGLANDGRANULES
ROE10.7%13.7%
ROCE15.1%15.5%
Net Margin16.18%11.15%
Operating Margin25.3%22.1%
Debt to Equity0.03x0.3x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricGLANDGRANULES
Promoter Holding51.83%37.67%
FII Holding8.74% 1.44 pp17.5% 2.19 pp
DII Holding30.44% 2.91 pp16.11% 0.9 pp
Public Holding9.05% 1.53 pp28.38% 1.28 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Gland Pharma Limited and Granules India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.